The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.

ABSTRACT:

Purpose

The purpose of this study is to describe the utilization of disease-modifying treatments (DMTs) in relapsing-remitting multiple sclerosis (MS) and assess the impact of both the introduction of new drugs and treatment recommendations (local recommendation on rituximab use issued at the largest MS clinic in Stockholm and regional Drug and Therapeutics Committee (DTC) recommendation on how dimethyl fumarate should be used).

Methods

Interrupted time series analyses using monthly data on all MS patients treated with DMTs in the Stockholm County, Sweden, from January 2011 to December 2017.

Results

There were 4765 individuals diagnosed with MS residing in the Stockholm County from 2011 to 2017. Of these, 2934 (62%) were treated with an MS DMT. Since 2011, fingolimod,

SUBMITTER: Eriksson I 

PROVIDER: S-EPMC5893684 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature